265 related articles for article (PubMed ID: 32742453)
1. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists.
Li S; Shen L
J Cancer; 2020; 11(17):5056-5068. PubMed ID: 32742453
[TBL] [Abstract][Full Text] [Related]
2. Advances in Radiobiology of Stereotactic Ablative Radiotherapy.
Qiu B; Aili A; Xue L; Jiang P; Wang J
Front Oncol; 2020; 10():1165. PubMed ID: 32850333
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity.
Goldsmith C; Plowman PN; Green MM; Dale RG; Price PM
Radiat Oncol; 2018 Oct; 13(1):204. PubMed ID: 30340643
[TBL] [Abstract][Full Text] [Related]
4. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
Akanda ZZ; Neeson PJ; John T; Barnett S; Hanna GG; Miller A; Jennens R; Siva S
Transl Lung Cancer Res; 2021 Jun; 10(6):2766-2778. PubMed ID: 34295676
[TBL] [Abstract][Full Text] [Related]
5. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
6. Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy.
Leung E; Gladwish A; Sahgal A; Lo SS; Kunos CA; Lanciano RM; Mantz CA; Guckenberger M; Zagar TM; Mayr NA; Chang AR; Jorcano S; Biswas T; Pontoriero A; Albuquerque KV
Radiat Oncol; 2020 Jan; 15(1):24. PubMed ID: 32000833
[TBL] [Abstract][Full Text] [Related]
7. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?
Brown JM; Carlson DJ; Brenner DJ
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):254-62. PubMed ID: 24411596
[TBL] [Abstract][Full Text] [Related]
8. Stereotactic ablative body radiotherapy (SABR) for effective palliation of metastases: factors affecting local control.
Patel PR; Kirkpatrick J; Salama JK; Nelson J; Broadwater G; Allen K; Clough R; Yin FF; Wang Z; Chang Z; Kelsey C; Ghafoori AP
J Radiosurg SBRT; 2014; 3(2):123-129. PubMed ID: 29296393
[TBL] [Abstract][Full Text] [Related]
9. The radiobiology of hypofractionation.
Nahum AE
Clin Oncol (R Coll Radiol); 2015 May; 27(5):260-9. PubMed ID: 25797579
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative body radiotherapy for lung cancer.
Franks KN; Jain P; Snee MP
Clin Oncol (R Coll Radiol); 2015 May; 27(5):280-9. PubMed ID: 25746732
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer.
Brown JM; Diehn M; Loo BW
Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):323-7. PubMed ID: 20832663
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.
Palma DA; Olson R; Harrow S; Correa RJM; Schneiders F; Haasbeek CJA; Rodrigues GB; Lock M; Yaremko BP; Bauman GS; Ahmad B; Schellenberg D; Liu M; Gaede S; Laba J; Mulroy L; Senthi S; Louie AV; Swaminath A; Chalmers A; Warner A; Slotman BJ; de Gruijl TD; Allan A; Senan S
BMC Cancer; 2019 Aug; 19(1):816. PubMed ID: 31426760
[TBL] [Abstract][Full Text] [Related]
14. HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR).
Song CW; Kim H; Cho H; Kim MS; Paek SH; Park HJ; Griffin RJ; Terezakis S; Cho LC
Cancers (Basel); 2022 Jul; 14(13):. PubMed ID: 35805044
[TBL] [Abstract][Full Text] [Related]
15. Blood T-cell profiling in metastatic melanoma patients as a marker for response to immune checkpoint inhibitors combined with radiotherapy.
Ratnayake G; Reinwald S; Edwards J; Wong N; Yu D; Ward R; Smith R; Haydon A; Au PM; van Zelm MC; Senthi S
Radiother Oncol; 2022 Aug; 173():299-305. PubMed ID: 35772575
[TBL] [Abstract][Full Text] [Related]
16. Implementation of Lung Stereotactic Ablative Radiotherapy at a Regional Cancer Centre.
Clayton R; Liu HW; Khan R; Udowicz M; Bayliss Y; Krobutschek K; Herring C; Lau H
J Med Imaging Radiat Sci; 2012 Dec; 43(4):245-252. PubMed ID: 31052011
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic ablative radiotherapy for primary renal cell carcinoma.
Yang DX; Kwon YS; Timmerman R; Hannan R
Clin Transl Radiat Oncol; 2024 Jan; 44():100705. PubMed ID: 38073715
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
19. Survey of the Patterns of Using Stereotactic Ablative Radiotherapy for Early-Stage Non-small Cell Lung Cancer in Korea.
Song S; Chang JH; Kim HJ; Kim YS; Kim JH; Ahn YC; Kim JS; Song SY; Moon SH; Cho MJ; Youn SM
Cancer Res Treat; 2017 Jul; 49(3):688-694. PubMed ID: 27809459
[TBL] [Abstract][Full Text] [Related]
20. Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series.
Qi X; Zhang ZF; Gao XS; Qin SB; Bai Y; Yu W; He Q; Fan Y; Zhang JH; Jiang Y; He ZS; Li HZ
Transl Androl Urol; 2023 Jan; 12(1):128-138. PubMed ID: 36760876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
